MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Float Percentage Of Total Shares Outstanding : 41.06% (As of May. 24, 2024)

View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MoonLake Immunotherapeutics's float shares is 25.82 Mil. MoonLake Immunotherapeutics's total shares outstanding is 62.87 Mil. MoonLake Immunotherapeutics's float percentage of total shares outstanding is 41.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MoonLake Immunotherapeutics's Insider Ownership is 5.64%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MoonLake Immunotherapeutics's Institutional Ownership is 25.52%.

MoonLake Immunotherapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MoonLake Immunotherapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	25.82	/	62.87
	=	41.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

MLTX:Mexico

Address

Dorfstrasse 29, Zug, CHE, 6300

Website

https://www.moonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Executives

Matthias Bodenstedt	officer: Chief Financial Officer	DORFSTRASSE 29, ZUG V8 6300
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge	director	DORFSTRASSE 29, ZUG V8 6300
Kristian Reich	officer: Chief Scientific Officer	DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge	director, officer: Chief Executive Officer	DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il	director, 10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier	director	DORFSTRASSE 29, ZUG V8 6300
Spike Loy	director	DORFSTRASSE 29, ZUG V8 6300
Kara Lassen	director	DORFSTRASSE 29, ZUG V8 6300